ClinicalTrials.gg

Program

HRS-8080

A development code. Also written as “HRS-8080 Tablet”, “HRS-6209 in Combination with HRS-8080” and “HRS-6209 in Combination with HRS-9813 and HRS-8080”.

In Jiangsu HengRui Medicine's pipeline, SERD. Its studies are mostly in Breast Neoplasms · Neoplasm Metastasis, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Jun 9, 202513 company-led studies, 10 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine1310 open or runningphase 3since Jun 9, 2025Dec 16, 2021Feb 2027phase 1 · NCT07876596
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-8080, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2021First study: phase 1 study in Neoplasm MetastasisFirst studyNCT05189717 · 156 planned · China
  2. Dec 4, 20232 phase 2 studies in Breast NeoplasmsNCT06222879, NCT06167694
  3. Aug 1, 2024Phase 2 study in Breast NeoplasmsNCT06555068 · 528 planned · China
  4. Sep 25, 2024Phase 1 study in Breast NeoplasmsNCT06619873 · 24 enrolled · China
  5. Nov 6, 2024Phase 2 study in Breast NeoplasmsNCT06679036 · 300 planned · China
  6. Jun 9, 2025Phase 3 study in Breast NeoplasmsNCT07024173 · 240 planned · China
  7. Nov 13, 2025Phase 1 study in Breast NeoplasmsNCT07229560 · 16 enrolled · China
  8. Dec 22, 2025Phase 1 study in Breast NeoplasmsNCT07320521 · 6 enrolled · China
  9. Jan 8, 20262 phase 3 studies in Breast NeoplasmsNCT07354022, NCT07349069
  10. Jan 29, 2026Phase 2 study in Advanced Unresectable or Metastatic Breast Cancer of AdultsNCT07389733 · 180 planned · China
  11. Oct 2, 2026Primary completion moved from 2026-12 to 2027-08Date moved laterphase 3 · +8 months · NCT07024173
  12. Oct 9, 2026Phase 1 study in Breast NeoplasmsNCT07876596 · 18 planned · China

Ahead

  1. Feb 2027Primary completion: phase 1 study in Breast NeoplasmsNCT07876596
  2. Aug 2027Primary completion: phase 3 study in Breast NeoplasmsNCT07024173
  3. Dec 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06555068
  4. Dec 2028Primary completion: phase 2 study in Advanced Unresectable or Metastatic Breast Cancer of AdultsNCT07389733

TargetBeta

“SERD”the company's pipeline, read by Claude · source

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07876596Breast Neoplasms · China1Not yet recruitingFeb 202718
NCT07389733Advanced Unresectable or Metastatic Breast Cancer of Adults · China2RecruitingDec 2028180
NCT07349069Breast Neoplasms · China3RecruitingDec 20305,500
NCT07354022Breast Neoplasms · China3RecruitingDec 2028912
NCT07320521Breast Neoplasms · China1CompletedJan 28, 20266
NCT07229560Breast Neoplasms · China1CompletedDec 31, 202516
NCT07024173Breast Neoplasms · China3RecruitingAug 2027240
NCT06679036Breast Neoplasms · China2RecruitingOct 30, 2026300
NCT06619873Breast Neoplasms · China1CompletedNov 13, 202424
NCT06555068Breast Neoplasms · China2RecruitingDec 2027528
NCT06222879Breast Neoplasms · China2RecruitingOct 31, 2026350
NCT06167694Breast Neoplasms · China2RecruitingJun 2026146
NCT05189717Neoplasm Metastasis · China1By invitationOct 31, 2024156

How it is read

Names in the registry

  • “HRS-8080”, 3 entries
  • “HRS-8080 Tablet”, 3 entries
  • “HRS-6209 in Combination with HRS-8080”, 1 entry
  • “HRS-6209 in Combination with HRS-9813 and HRS-8080”, 1 entry
  • “[14C]HRS-8080”, 1 entry

Codes read as this program: HRS8080.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.